Glioblastoma is the most common primary malignant brain tumor in adults and is associated
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …

Glioblastoma is the most common primary central nervous system malignancy and has a
poor prognosis. Standard first-line treatment, which includes surgery followed by adjuvant …

Background We sought to ascertain the immune effector function of pembrolizumab within
the glioblastoma (GBM) microenvironment during the therapeutic window. Methods In an …

Importance Clinical outcomes for glioblastoma remain poor. Treatment with immune
checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from …

Primary brain tumors, such as glioblastoma (GBM), are remarkably resistant to
immunotherapy, even though pre-clinical models suggest effectiveness. To understand this …

Background Immunotherapies have demonstrated efficacy across a diverse set of tumors
supporting further evaluation in glioblastoma. The objective of this study was to evaluate the …

Introduction Despite recent advances in treatment for a number of cancers with immune
checkpoint blockade (ICB), immunotherapy has had limited efficacy in glioblastoma (GBM) …

Immune checkpoint inhibitors (CIs) have changed the landscape of tumor immunotherapy.
Glioblastoma (GBM) remains the most common primary malignant brain tumor in adults and …

Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with
checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this …

Immune checkpoint inhibitors have been successful across several tumor types; however,
their efficacy has been uncommon and unpredictable in glioblastomas (GBM), where< 10 …